Can a Biopsy Spread Cancer?

One of the questions patients ask most often before a biopsy is: "If the needle enters the mass, won’t cells scatter?" Medicine has a name for this concern: needle-tract seeding — the possibility of tumour cells being carried along the path of the needle.

The worry is fed mostly by individual stories circulating online and by older case reports. Such reports exist in the medical literature; but the existence of individual cases is not, by itself, a verdict on the general safety of the method. Today’s practice — image guidance, fine-calibre needles and planned access routes — differs markedly from the era in which many of those reports were written.

The needle used for fine-needle aspiration of thyroid nodules is finer than the one used for drawing blood. There is no reliable evidence that this method spreads cancer; it is the international standard route to a definitive diagnosis of thyroid nodules and is performed in large numbers worldwide every day.

The same holds for breast biopsy: there is no reliable evidence that fine-needle or core (tru-cut) breast biopsy spreads cancer. Since no treatment plan can be built without a tissue diagnosis, biopsy is the step that prevents unnecessary surgery in breast lesions.

Needle-tract seeding has been reported in core biopsies of organs such as the liver, kidney, lung and pancreas — but it is reported only very rarely. International interventional radiology guidelines define these procedures as standard practice because of their diagnostic value.

What keeps the risk low is not chance but technique: the access route is planned on imaging in advance; the needle’s progress is followed in real time on screen; where appropriate a coaxial (sheathed) technique is used — a single skin entry is made and all samples are taken through that thin sheath, minimising the needle’s contact with tissue.

Experience is part of the technique as well: choosing the shortest, safest route to the target, avoiding vessels and neighbouring structures, and matching the number of samples to what pathology requires — together, these keep the risk small.

For soft-tissue masses with a possibility of sarcoma, the needle’s entry route is chosen to lie within the line of a possible future operation, so that if surgery is needed the needle tract is removed with the specimen. This is a core principle of international sarcoma guidelines, and the reason such biopsies are planned in coordination with the surgical team.

For some diagnoses the needle is deliberately avoided: suspected hydatid cyst of the liver is the well-known example. Such a cyst should not be punctured without precautions; the diagnosis is made with imaging and, where needed, blood tests, and treatment follows its own protocol under antiparasitic drug cover. There is no rule that says "every mass gets a biopsy first" — your physician determines the correct sequence.

Postponing a biopsy out of fear of seeding has a cost: oncological treatment cannot be started, unnecessary surgery cannot be ruled in or out, and no follow-up plan can be built without a tissue diagnosis. Time spent not knowing what a mass is does not change the disease’s own course — it only delays the start of the right treatment.

The decision framework is therefore this: a biopsy is planned when its result will change the treatment; when imaging findings are typical enough, a decision may be made without one. Which path fits you is determined by evaluating the examination and the imaging together.